Points to consider: efficacy and safety evaluations in the clinical development of ultra-orphan drugs
Crossref DOI link: https://doi.org/10.1186/s13023-017-0690-5
Published Online: 2017-08-23
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Maeda, Kojiro
Kaneko, Masayuki
Narukawa, Mamoru
Arato, Teruyo
Funding for this research was provided by:
Health Labour Sciences Research Grant from Japan's Ministry of Health, Labour and Welfare